ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.499,93
-0,54%
S&P 500
5.631,22
0,28%
Dow Jones
40.211,72
0,53%
Euro vs US Dollar
1,08976
-0,02%
Bitcoin
63.685,77
-1,80%
Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. AstraZeneca PLC (AZN)

  7. AstraZeneca PLC (AZN) News

AZN

AstraZeneca (AZN)

AstraZeneca PLC
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:AZN
DatumZeitQuelleÜberschriftSymbolFirma
27/07/202313h00Business WireENHERTU® (fam-trastuzumab deruxtecan-nxki) Demonstrated Clinically Meaningful Progression-Free Survival and Overall Survival Across Multiple HER2-Expressing Advanced Solid Tumors in DESTINY-PanTumor02 Phase II TrialNASDAQ:AZNAstraZeneca PLC
21/07/202306h24Dow Jones NewsSK Chemicals' Shares Climb After AstraZeneca DealNASDAQ:AZNAstraZeneca PLC
05/07/202313h55IH Market NewsWednesday’s Wall Street Highlights: Meta, Amazon, Rivian, Pfizer, UPS and MoreNASDAQ:AZNAstraZeneca PLC
03/07/202323h40IH Market NewsU.S. Stocks Finish Abbreviated Trading Session Modestly HigherNASDAQ:AZNAstraZeneca PLC
03/07/202320h03ValueWalkTesla Stock Jumps 7% On Earnings BeatNASDAQ:AZNAstraZeneca PLC
03/07/202317h19Dow Jones NewsAstrazeneca Down Over 7%, on Pace for Largest Percent Decrease Since December 2020 -- Data TalkNASDAQ:AZNAstraZeneca PLC
03/07/202314h04Dow Jones NewsAstraZeneca Lung Cancer Treatment Meets Dual Primary Endpoint in First Phase 3 Trial ResultsNASDAQ:AZNAstraZeneca PLC
03/07/202313h00Business WireDatopotamab Deruxtecan Met Dual Primary Endpoint of Progression-Free Survival in Patients With Advanced Non-Small Cell Lung Cancer in TROPION-Lung01 Phase III TrialNASDAQ:AZNAstraZeneca PLC
03/07/202311h43Dow Jones NewsTrending: AstraZeneca Shares Fall on Disappointing Datopotamab Deruxtecan TrialNASDAQ:AZNAstraZeneca PLC
03/07/202308h50Dow Jones NewsAstraZeneca Says Datopotamab Deruxtecan Phase 3 Trial Shows Positive Results in Lung Cancer PatientsNASDAQ:AZNAstraZeneca PLC
29/06/202316h15Dow Jones NewsAstraZeneca Sees Positive Phase 3 Trial Data for Imfinzi Cancer TreatmentNASDAQ:AZNAstraZeneca PLC
29/06/202316h02Dow Jones NewsAstraZeneca's Advanced Liver Cancer Treatment Data Shows Improved Survival RatesNASDAQ:AZNAstraZeneca PLC
29/06/202315h15Business WireIMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) demonstrated sustained overall survival benefit in advanced liver cancer with an unprecedented one in four patients alive at four years in HIMALAYA Phase III trialNASDAQ:AZNAstraZeneca PLC
29/06/202310h32Business WireAstraZeneca annonce un investissement de 400 millions de dollars dans la reforestation et la biodiversité pour contribuer à la lutte contre le changement climatique et à la protection de la santé des populationsNASDAQ:AZNAstraZeneca PLC
28/06/202323h28Edgar (US Regulatory)Annual Report of Employee Stock Plans (11-k)NASDAQ:AZNAstraZeneca PLC
28/06/202323h28Edgar (US Regulatory)Form 11-K - Annual report of employee stock purchase, savings and similar plansNASDAQ:AZNAstraZeneca PLC
28/06/202315h23Business WireAstraZeneca investiert 400 Millionen Dollar in die Wiederaufforstung und die biologische Vielfalt, um den Klimaschutz und die menschliche Gesundheit zu unterstützenNASDAQ:AZNAstraZeneca PLC
28/06/202308h00Business WireAstraZeneca announces $400 million investment in reforestation and biodiversity in support of climate action and human healthNASDAQ:AZNAstraZeneca PLC
27/06/202312h51Dow Jones NewsTrending: AstraZeneca's Diabetes Treatment Approved in ChinaNASDAQ:AZNAstraZeneca PLC
19/06/202307h46Dow Jones NewsAstraZeneca Has Plans to Spin Off China Business, the Financial Times ReportsNASDAQ:AZNAstraZeneca PLC
19/06/202301h47KR Market News아스트라제네카, 중국 사업 분사 및 상장 계획 – FTNASDAQ:AZNAstraZeneca PLC
13/06/202313h00Business WireAstraZeneca announces innovative partnership with Vanguard Renewables to decarbonize its United States sitesNASDAQ:AZNAstraZeneca PLC
13/06/202308h58Dow Jones NewsAstraZeneca's Soliris Treatment Approved in China for Adults With gMGNASDAQ:AZNAstraZeneca PLC
12/06/202313h00Business WireCapivasertib in combination with FASLODEX® (fulvestrant) granted Priority Review in the US for patients with advanced HR-positive breast cancerNASDAQ:AZNAstraZeneca PLC
09/06/202312h04Dow Jones NewsTrending: AstraZeneca Reaches Treg Cell Therapies Agreement With Quell TherapeuticsNASDAQ:AZNAstraZeneca PLC
09/06/202309h10Dow Jones NewsAstraZeneca Says Nirsevimab Recommended for RSV Prevention in Infants by FDA BodyNASDAQ:AZNAstraZeneca PLC
09/06/202308h52Dow Jones NewsAstraZeneca Reaches Agreement With Quell Therapeutics for Treg Cell TherapiesNASDAQ:AZNAstraZeneca PLC
05/06/202314h53Dow Jones NewsAstraZeneca Cancer Drug Enhertu Shows Clinically Meaningful, Durable Response in TrialNASDAQ:AZNAstraZeneca PLC
05/06/202314h05Business WireDatopotamab deruxtecan combinations showed encouraging tumor responses in patients with advanced non-small cell lung cancer in TROPION-Lung02 Phase Ib trialNASDAQ:AZNAstraZeneca PLC
05/06/202314h00Business WireENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated clinically meaningful and durable responses in patients across multiple HER2-expressing advanced solid tumorsNASDAQ:AZNAstraZeneca PLC
 Showing the most relevant articles for your search:NASDAQ:AZN

Kürzlich von Ihnen besucht

PM
XAUUSD
Gold vs US Dollar
FX
EURGBP
Euro vs Sterling
NASDAQ
AMZN
Amazon.com
CCOM
US100
US Tech 100
COIN
SOLUSD
Solana
NYSE
MRK
Merck
CCOM
US30
US 30
COIN
BTCUSD
Bitcoin
DBI
SDXP
SDAX
TG
BAS
BASF
COIN
ETHUSD
Ethereum
TG
RHM
Rheinmetall
NASDAQ
NVDA
NVIDIA
CCOM
SILVER
SILVER
TG
MBG
MercedesBenz
USOTC
BASFY
BASF (QX)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten